Welcome to our dedicated page for Ispecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you track a niche biotech like iSpecimen, the real story hides in its filings. Revenue swings tied to specimen sourcing fees, new hospital network deals, and compliance costs appear first in the 10-K annual report. If you are searching for the “iSpecimen annual report 10-K simplified,” this page delivers it—along with AI-generated plain-English highlights that extract segment margins and supplier concentrations.
Quarterly trends matter just as much. Our platform streams each “iSpecimen quarterly earnings report 10-Q filing” the moment it hits EDGAR and pairs it with concise commentary on cash burn, backlog, and bookings. Material developments—new biobank partnerships, regulatory notices, or leadership changes—surface through “iSpecimen 8-K material events explained,” so you never miss a turning point. Need to monitor executive behavior? Real-time alerts flag every “iSpecimen Form 4 insider transactions real-time,” letting you see “iSpecimen executive stock transactions Form 4” in context of upcoming earnings.
Stock Titan’s AI goes beyond simple aggregation. It answers natural questions investors actually ask: “iSpecimen SEC filings explained simply,” “How do I interpret the iSpecimen proxy statement executive compensation?,” or “What drives cash flow in the latest iSpecimen earnings report filing analysis?” With comprehensive coverage, automatic summaries, and keyword search across every form type, our portal turns hundreds of pages into actionable insight—helping you understand “understanding iSpecimen SEC documents with AI” without wading through technical prose.
iSpecimen Inc. (ISPC) is soliciting votes for a virtual Special Meeting on September 26, 2025 at 10:00 a.m. ET to approve six proposals focused on capital structure and financing. The centerpiece is a board-authorized reverse stock split ranging from one-for-ten (1:10) to one-for-one hundred (1:100) intended to help meet Nasdaq's $1.00 minimum bid requirement. The board also seeks to increase authorized shares from 250,000,000 to 500,000,000, and to obtain shareholder approval under Nasdaq rules to permit future non-public financings and an equity line that may exceed 19.99% of outstanding stock. The company proposes to amend certain convertible securities to raise the conversion floor from 50% to 80% of VWAP, which may reduce shares issued on conversion. The proxy materials state a Record Date of July 25, 2025, note a 34% quorum, and list two different outstanding share counts in the filing (3,979,517 and 5,539,345), an inconsistency disclosed in the document. Proxy materials are available at proxyvote.com and distribution began on or about August 11, 2025.
iSpecimen Inc. (Nasdaq: ISPC) has filed Amendment No. 3 to its Form S-1 registration statement, signaling a forthcoming underwritten public offering of common stock and pre-funded warrants. The company plans to sell an unspecified number of shares and, for investors whose post-offering ownership would otherwise exceed 4.99% (optionally 9.99%), an equivalent number of pre-funded warrants priced at the offering price minus $0.0001 with a de-minimis $0.0001 exercise price. Both securities will be issued in a single closing on a firm-commitment basis led by WestPark Capital.
Key structural details:
- The final share count, public offering price, and gross proceeds will be determined at pricing; blanks remain in the filing.
- The company is a non-accelerated filer, smaller reporting company, and emerging growth company.
- Underwriter compensation includes customary cash fees plus up to $110,000 in reimbursable legal and out-of-pocket expenses.
- No listing is planned for the pre-funded warrants, limiting their secondary-market liquidity.
The filing emphasizes that the prospectus is preliminary, forward-looking statements are subject to risk, and no sales can occur until the SEC declares the registration effective.
iSpecimen announced significant changes to its Board of Directors on June 18, 2025. Richard J. Paolone (Chairman since February 2025) and John L. Brooks III (board member since June 2021) have resigned from the Board, effective immediately. Neither resignation involved disagreements with the company's operations, policies, or practices.
The Board appointed Anthony Lau as a new director on June 20, 2025. Lau brings significant experience as:
- CEO and CFO of Remington Resources (CSE-listed company) since 2021
- Expert in corporate governance and public company compliance
- Engineering professional in oil and gas infrastructure since 2014
Following these changes, the Board committees were restructured:
- Audit Committee: Lau (Chair), Dhaliwal, Yang
- Compensation Committee: Yang (Chair), Lau, Dhaliwal
- Nominating and Corporate Governance Committee: Dhaliwal (Chair), Yang, Lau
FAQ
What is the current stock price of Ispecimen (ISPC)?
What is the market cap of Ispecimen (ISPC)?
